NCT02607254View on ClinicalTrials.gov

Efficacy and Safety of Pregabalin in Treatment of Neuropathic Pain in Patients With Idiopathic Small Fiber Neuropathy

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

July 31, 2018

Study Completion Date

July 31, 2018

Conditions

Idiopathic Small Fiber Neuropathy

Interventions

DRUG

Pregabalin

Pregabalin will be given to the patients, starting at 75 mg BID and increased weekly to reach 225 mg BID for 8 weeks. During withdrawal phase, dose of pregabalin will be kept the same for patients who are randomized to the pregabalin withdrawal group.

DRUG

Placebo

Placebo will be given to the patients that are randomized to placebo during withdrawal phase.

Trial Locations (1)

21287

Johns Hopkins Hospital, Baltimore